ArticleScientific reports2017
Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 93 citations in OpenAlex.
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- Differential expression of immune checkpoint VISTA in inflammatory skin diseases.The Journal of investigative dermatology · 2026Article
- Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies.Scientific reports · 2026Article
- Paired comparison of tumor core and airway lumen (BALF) microbiomes in lung adenocarcinoma: deciphering specificFrontiers in cellular and infection microbiology · 2026Article
- On the same side: VISTA and its ligands interact in cis on the cell surface.Protein science : a publication of the Protein Society · 2026Article
- VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies.Immune network · 2025Review
- A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression.Cancer research · 2025Article
- Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.British journal of cancer · 2025Article
- Aberrant Expression ofCancers · 2025Article
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- Uncovering the mysteries of human gamma delta T cells: from origins to novel therapeutics.Frontiers in immunology · 2025Review
- Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.Frontiers in immunology · 2025Review
- Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4International journal of drug discovery and pharmacology · 2024Article
- VISTA-mediated immune evasion in cancer.Experimental & molecular medicine · 2024Review
- VISTA nonredundantly regulates proliferation and CD69low γδ T cell accumulation in the intestine in murine sepsis.Journal of leukocyte biology · 2024Article
- Small-molecule agents for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Review
- Review
- Association Between VISTA and Vascular Cognitive Impairment in Older Chinese Adults: A Cross-Sectional Study.Clinical interventions in aging · 2024Article
- VISTA in hematological malignancies: a review of the literature.Frontiers in immunology · 2024Review
- VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.Cancer cell international · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 7 institutions in 3 countries.
Na LiDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Wenwen XuDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Ying YuanDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Natarajan AyithanDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Yasutomo ImaiDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Xuesong WuDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Halli MillerDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.ORCID 0000-0003-2609-4482
Michael OlsonDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Yunfeng FengDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Yina H HuangDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0002-0125-9351
Mary Jo TurkDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Samuel T HwangDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Subramaniam MalarkannanDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA.
Li WangDepartment of Microbiology and Immunology, Milwaukee, WI, 53226, USA. Lilywang@mcw.edu.ORCID 0000-0003-3473-5833
Dartmouth College · USUniversity of Wisconsin–Milwaukee · USMedical College of Wisconsin · USHarbin Medical University · CNHyogo Medical University · JPShanghai University of Traditional Chinese Medicine · CNUniversity of Maryland, Baltimore · US
Funding
PIP3-INDEPENDENT REGULATION OF AKT1 ACTIVITY IN T CELLSR01AI089805 · NIAID · WASHINGTON UNIVERSITY · PI HUANG, YINA HSING · 2011 to 2021
$4.2MVISTA, a novel checkpoint that suppresses anti-tumor T cell responsesR01CA164225 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI WANG, LI LILY · 2012 to 2023
$3.3MMechanisms of concomitant tumor immunity and autoimmunityR01CA120777 · NCI · DARTMOUTH COLLEGE · PI TURK, MARY JO · 2006 to 2016
$2.5MFunction and Targeting of CCR6/CCL20 in Autoimmune Psoriasiform Skin DiseaseR01AR063091 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HWANG, SAM T · 2013 to 2017
$1.6MMolecular signature of inflammationR01CA179363 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI MALARKANNAN, SUBRAMANIAM · 2014 to 2018
$1.6MMolecular mechanisms of signaling co-ordination in innate lymphocytesR01AI102893 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI MALARKANNAN, SUBRAMANIAM · 2013 to 2016
$1.5MNCI NIH HHS R01 CA120777NCI NIH HHS R01 CA164225NCI NIH HHS R01 CA179363NIAID NIH HHS R01 AI089805NIAID NIH HHS R01 AI102893NIAMS NIH HHS R01 AR063091Worldwide Cancer Research 16-1161
Abstract
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an inhibitory immune-checkpoint molecule that suppresses CD4
Indexed as
Immunity, InnateAnimalsCytokinesImiquimodInflammationInflammation MediatorsInterleukin-17Interleukin-23Intraepithelial LymphocytesMembrane ProteinsMice, KnockoutPsoriasisSignal TransductionTh17 CellsCytokinesImiquimodInflammation MediatorsInterleukin-17Interleukin-23Membrane ProteinsVsir protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.